AllSci News
Idorsia secures USD 278m debt facility to extend runway as insomnia franchise scales
Switzerland-based Idorsia Pharmaceuticals Ltd (SWX: IDIA) confirmed the closing of a senior secured term loan facility of up to CHF 250 million...
Ligand raises USD 700m to fund USD 739m XOMA royalty acquisition
Jupiter, Florida-based Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced the closing of a USD 700 million offering of 0.00% convertible senior...
Boehringer Ingelheim taps Immunai’s AI to map T-cell targets across cancer and autoimmune disease
Boehringer Ingelheim and New York-based Immunai announced a multi-project discovery collaboration valued at up to USD 15 million, extending through 2027, focused…
Arcus enters immunology with first-in-human MRGPRX2 antagonist for atopic disease
Arcus Biosciences (NYSE: RCUS) has registered a first-in-human trial of AB102, an oral small-molecule antagonist of MRGPRX2 (Mas-related G-protein-coupled...
Nuvation Bio raises USD 250m in convertible notes
New York-based Nuvation Bio, Inc. (NYSE: NUVB) announced the pricing of an upsized convertible senior notes offering totaling USD 250 million, with proceeds...
Arrowhead launches mysterious RNAi candidate ARO-033 with undisclosed target and mechanism
Arrowhead Pharmaceuticals (Nasdaq: ARWR) has registered a first-in-human trial for ARO-033, an investigational subcutaneous agent that appears to be derived...
MaaT Pharma challenges EMA rejection of Xervyteg with re-examination request for aGvHD
France-based MaaT Pharma (Euronext: MAAT) has announced its intention to request a re-examination of the negative opinion issued by the European Medicines...
HSS researchers uncover hidden driver of rheumatoid arthritis beyond inflammation
Researchers at the Hospital for Special Surgery (HSS) Research Institute in New York have identified a distinct immune cell population that appears to drive...
Optimeos secures backing for non-viral nano gene therapy delivery
Princeton, New Jersey-based Optimeos Life Sciences has announced an investment from Hatch BioFund, an early-stage life sciences venture capital firm...
Otsuka reports positive Phase IIIb anxiety data as centanafadine nears July FDA decision
Otsuka has reported positive Phase IIIb results for centanafadine sustained-release in adults with ADHD and comorbid anxiety, a readout that matters because...
University of Pennsylvania investigates discontinuing anti-CD20 therapy in relapsing MS
The University of Pennsylvania has received a USD 1.34 million NIH U01 award to conduct a randomized, placebo-controlled trial testing whether ocrelizumab...
Epitopea's mRNA vaccine targets ovarian cancer's treatment-resistant majority with first-in-human trial
Epitopea's mRNA cancer vaccine CryptiVax-1001 enters first-in-human testing in ovarian cancer's hardest-to-treat subgroup
HUTCHMED's fanregratinib posts pivotal Phase II data as China NDA enters priority review
HUTCHMED's fanregratinib demonstrated a 42.5% objective response rate in pretreated patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma,...
Mwyngil reports one of the first public in vivo datasets for GPR75 obesity program
Boston-based Mwyngil Therapeutics reported preclinical proof-of-concept data for its GPR75 inverse agonist obesity program, with lead oral compounds...
Lycia raises USD 75m to advance novel extracellular protein degradation into early clinical trials
South San Francisco-based Lycia Therapeutics, Inc., a clinical-stage biotechnology company developing therapeutics designed to degrade disease-causing...
The AllSci Brief
Systematic R&D and deal news. Daily.